57 results
F-6
EX-99
IMCR
Immunocore Holdings plc
27 Jan 21
Registration for ADRs (foreign)
5:30pm
Exhibit (d)
January 27, 2021
Citibank, N.A. – ADR Department
388 Greenwich Street
New York, New York 10013
Ladies and Gentlemen:
We refer
6-K
EX-99.3
IMCR
Immunocore Holdings plc
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
approval is received.
In the third quarter, the Australian Government Department of Health granted tebentafusp Orphan Drug Designation. Additionally … , the Australian Government Department of Health has accepted the Marketing Application for tebentafusp in mUM, and the company (through the Adjutor
6-K
EX-99.1
IMCR
Immunocore Holdings plc
14 Apr 22
Current report (foreign)
4:11pm
within the Nuffield Department of Medicine at the University of Oxford. Previously, Professor Sir Peter Ratcliffe served as Nuffield Professor and Head … of the Nuffield Department of Clinical Medicine from 2004 to 2016. In 2019, Professor Sir Peter Ratcliffe was awarded the Nobel Prize for Physiology
10-K
2023 FY
EX-10.14
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
of Department; should jury service be required this will be on a paid leave of absence basis.
Should you be called on to perform jury service, you should … a member of the HR department, as early as possible on the first day of absence. You must explain the reason for your absence and give as much
6-K
EX-99.1
IMCR
Immunocore Holdings plc
11 Jul 22
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
4:05pm
.
Professor Sarah Fidler, PhD, Imperial College of London Department of Infectious Disease commented: “There are nearly 38 million people around
6-K
EX-99.1
bwzhqq gcxoh
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.1
z9qs8soe 3tx
4 Apr 22
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
4:06pm
6-K
EX-99.1
d23z1ga
20 Jul 22
Securities Purchase Agreement
4:06pm
6-K
EX-99.1
o5pt239bfa68bfw
26 Jan 22
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
4:29pm
6-K
EX-99.2
uoe6 8ylu5utmkgg3t
20 Jul 22
Securities Purchase Agreement
4:06pm
F-1
EX-10.6
9xi3 ilx3vf2d
15 Jan 21
Registration statement (foreign)
4:57pm
DRS/A
EX-10.5
2cbr0tsgl2vlj92f
22 Dec 20
Draft registration statement (amended)
12:00am
6-K
EX-99.1
xi86zs b4i0f5wrbtv
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
1rn0kr
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am
F-1/A
EX-1.1
dr8zs26k9omluwzqrr
1 Feb 21
Registration statement (foreign) (amended)
6:21am
F-1/A
EX-1.1
pnvhq
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
DRS/A
EX-10.4
7nyvl5nvoh30v9zh
22 Dec 20
Draft registration statement (amended)
12:00am
F-1
EX-10.5
hxa ty5s2b2pt
15 Jan 21
Registration statement (foreign)
4:57pm
6-K
EX-99.1
63g6zi52y 9xman0d
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
DRS/A
EX-10.6
h39s5b yc
22 Dec 20
Draft registration statement (amended)
12:00am